Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline

Core Insights - Oncotelic Therapeutics, Inc. has made significant progress in 2025, transitioning from platform build-out to execution and validation, with a focus on oncology, immunotherapy, and CNS-related diseases [1][2] Group 1: Key Accomplishments in 2025 - The company unveiled its proprietary AI-enabled knowledge platform, PDAOAI, which supports biomarker discovery and translational hypothesis generation [3] - Oncotelic completed a Phase 1 clinical trial of OT-101 in combination with IL-2 and advanced its IV everolimus Deciparticle™ program into first-in-human clinical testing [4] - The Deciparticle™ platform was validated through coordinated data releases, establishing it as a differentiated delivery technology for oncology [5] - Multiple peer-reviewed studies were published, reinforcing Oncotelic's leadership in TGFB2-centric biology and linking TGFB2 expression to survival outcomes in various cancers [6] - A strategic partnership with Medicilon was established to enhance rapid IND-enabling capabilities, complementing the company's global regulatory strategy [7] - An independent analysis valued the GMP Bio joint-venture pipeline at approximately $1.7 billion, strengthening Oncotelic's asset-level valuation narrative [8] Group 2: Strategic Direction for 2026 - The company plans to build on its 2025 progress with a focus on continued development momentum, capital allocation, and strategic execution [10] - Priorities include completing a second independent U.S.-based valuation for its 45% equity interest in the GMP Bio joint venture [10] - Oncotelic aims to advance clinical programs, evaluate regulatory pathways, explore partnership opportunities, and strengthen operational readiness for future growth [16]